



Liver Cancers Molecular Biomarkers Predicting Outcome

Guest Editor:

Dr. Nima Kokabi

Division of Interventional
Radiology and Image-Guided
Medicine, Department of
Radiology and Imaging Sciences,
Emory University, Atlanta, GA
30308, USA

Deadline for manuscript
submissions:
closed (10 July 2024)

Message from the Guest Editor

Dear Colleagues,

We are pleased to invite you to participate in this Special Issue, entitled “Liver Cancers Molecular Biomarkers Predicting Outcome”.

The aim of this edition of *Cancers* is to review the most relevant imaging, clinical and molecular biomarkers of liver cancers pertaining to liver-directed therapy. Additionally, we will review relevant targets for immunotherapy in combination with liver-directed therapy. The role of artificial intelligence in facilitating the use of biomarkers in liver-directed therapies will also be explored. Particular attention will be paid to exploring tumor hypoxia and its implications for treatment resistance and systematization.

I look forward to receiving your contributions.

Dr. Nima Kokabi
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)